Beda Joos

Summary

Affiliation: University Hospital
Country: Switzerland

Publications

  1. ncbi request reprint Equal amounts of intracellular and virion-enclosed hepatitis C virus RNA are associated with peripheral-blood mononuclear cells in vivo
    Philipp Kaiser
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, 8032 Zurich, Switzerland
    J Infect Dis 194:1713-23. 2006
  2. ncbi request reprint Association between specific HIV-1 Env traits and virologic control in vivo
    Beda Joos
    University Hospital Zurich, Department of Medicine, Switzerland
    Infect Genet Evol 10:365-72. 2010
  3. pmc HIV rebounds from latently infected cells, rather than from continuing low-level replication
    Beda Joos
    Department of Medicine, Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, CH 8091 Zurich, Switzerland
    Proc Natl Acad Sci U S A 105:16725-30. 2008
  4. pmc Long-term multiple-dose pharmacokinetics of human monoclonal antibodies (MAbs) against human immunodeficiency virus type 1 envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5)
    Beda Joos
    University Hospital Zurich, Infectious Diseases and Hospital Epidemiology, Ramistrasse 100, CH 8091 Zurich, Switzerland
    Antimicrob Agents Chemother 50:1773-9. 2006
  5. pmc Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors
    Peter Rusert
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Ramistrasse 100, 8091 Zurich, Switzerland
    J Virol 79:8454-69. 2005
  6. ncbi request reprint Positive in vivo selection of the HIV-1 envelope protein gp120 occurs at surface-exposed regions
    Beda Joos
    Department of Medicine, Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, CH 8091, Switzerland
    J Infect Dis 196:313-20. 2007
  7. pmc Low human immunodeficiency virus envelope diversity correlates with low in vitro replication capacity and predicts spontaneous control of plasma viremia after treatment interruptions
    Beda Joos
    University Hospital Zurich, Department of Medicine, Division of Infectious Diseases and Hospital Epidemiology, Ramistrasse 100, CH 8091 Zurich, Switzerland
    J Virol 79:9026-37. 2005
  8. pmc In vivo efficacy of human immunodeficiency virus neutralizing antibodies: estimates for protective titers
    Alexandra Trkola
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Ramistrasse 100, 8091 Zurich, Switzerland
    J Virol 82:1591-9. 2008
  9. pmc Productive human immunodeficiency virus type 1 infection in peripheral blood predominantly takes place in CD4/CD8 double-negative T lymphocytes
    Philipp Kaiser
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zürich Rämistrasse, 100 8091 Zürich, Switzerland
    J Virol 81:9693-706. 2007
  10. doi request reprint Origin of minority drug-resistant HIV-1 variants in primary HIV-1 infection
    Karin J Metzner
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland
    J Infect Dis 208:1102-12. 2013

Detail Information

Publications34

  1. ncbi request reprint Equal amounts of intracellular and virion-enclosed hepatitis C virus RNA are associated with peripheral-blood mononuclear cells in vivo
    Philipp Kaiser
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, 8032 Zurich, Switzerland
    J Infect Dis 194:1713-23. 2006
    ..Quantitation of HCV RNA with regard to its subcellular distribution and longitudinal course is needed for better understanding of the largely unexplored in vivo dynamics and potential pathogenetic significance of HCV in PBMCs...
  2. ncbi request reprint Association between specific HIV-1 Env traits and virologic control in vivo
    Beda Joos
    University Hospital Zurich, Department of Medicine, Switzerland
    Infect Genet Evol 10:365-72. 2010
    ..These residues in HIV gp120 might affect in vivo HIV-1 fitness either at the level of Env function or influence susceptibility to adaptive or innate immune response...
  3. pmc HIV rebounds from latently infected cells, rather than from continuing low-level replication
    Beda Joos
    Department of Medicine, Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, CH 8091 Zurich, Switzerland
    Proc Natl Acad Sci U S A 105:16725-30. 2008
    ..Furthermore, a prolonged delay in restoration of pretreatment viral diversity after treatment interruption demonstrates a surprisingly sustained evolutionary bottleneck induced by punctuated antiretroviral therapy...
  4. pmc Long-term multiple-dose pharmacokinetics of human monoclonal antibodies (MAbs) against human immunodeficiency virus type 1 envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5)
    Beda Joos
    University Hospital Zurich, Infectious Diseases and Hospital Epidemiology, Ramistrasse 100, CH 8091 Zurich, Switzerland
    Antimicrob Agents Chemother 50:1773-9. 2006
    ..Further studies examining tissue concentrations to explain the differential in vivo activity of the anti-gp120 antibody compared with those of the two anti-gp41 antibodies are warranted...
  5. pmc Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors
    Peter Rusert
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Ramistrasse 100, 8091 Zurich, Switzerland
    J Virol 79:8454-69. 2005
    ..Activities of these MAbs correlated significantly with each other, suggesting that common features of the viral envelope modulate their potencies...
  6. ncbi request reprint Positive in vivo selection of the HIV-1 envelope protein gp120 occurs at surface-exposed regions
    Beda Joos
    Department of Medicine, Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, CH 8091, Switzerland
    J Infect Dis 196:313-20. 2007
    ....
  7. pmc Low human immunodeficiency virus envelope diversity correlates with low in vitro replication capacity and predicts spontaneous control of plasma viremia after treatment interruptions
    Beda Joos
    University Hospital Zurich, Department of Medicine, Division of Infectious Diseases and Hospital Epidemiology, Ramistrasse 100, CH 8091 Zurich, Switzerland
    J Virol 79:9026-37. 2005
    ....
  8. pmc In vivo efficacy of human immunodeficiency virus neutralizing antibodies: estimates for protective titers
    Alexandra Trkola
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Ramistrasse 100, 8091 Zurich, Switzerland
    J Virol 82:1591-9. 2008
    ..Equally, this raises hopes that a preventive vaccine could become effective at comparatively lower neutralizing antibody titers...
  9. pmc Productive human immunodeficiency virus type 1 infection in peripheral blood predominantly takes place in CD4/CD8 double-negative T lymphocytes
    Philipp Kaiser
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zürich Rämistrasse, 100 8091 Zürich, Switzerland
    J Virol 81:9693-706. 2007
    ....
  10. doi request reprint Origin of minority drug-resistant HIV-1 variants in primary HIV-1 infection
    Karin J Metzner
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland
    J Infect Dis 208:1102-12. 2013
    ..They may result from de novo mutagenesis or transmission. To date, the latter has not been proven...
  11. pmc Early antiretroviral therapy during primary HIV-1 infection results in a transient reduction of the viral setpoint upon treatment interruption
    Viktor von Wyl
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
    PLoS ONE 6:e27463. 2011
    ..Long-term benefits of combination antiretroviral therapy (cART) initiation during primary HIV-1 infection are debated...
  12. ncbi request reprint Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies
    Alexandra Trkola
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Ramistrasse 100, 8091 Zurich, Switzerland
    Nat Med 11:615-22. 2005
    ....
  13. pmc In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10
    Amapola Manrique
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Ramistrasse 100, 8091 Zurich, Switzerland
    J Virol 81:8793-808. 2007
    ..This remarkable vulnerability of the virus to interference within the MPER calls for a further evaluation of the safety and efficacy of MPER-targeting therapeutic and vaccination strategies...
  14. pmc Biphasic decay kinetics suggest progressive slowing in turnover of latently HIV-1 infected cells during antiretroviral therapy
    Marek Fischer
    University Hospital Zurich, Division of Infectious Diseases, Ramistrasse 100, 8092 Zurich, Switzerland
    Retrovirology 5:107. 2008
    ..These cells persisted during cART. Nevertheless, during the first four weeks of therapy their kinetics resembled that of productively infected cells...
  15. ncbi request reprint Quantification of infectious HIV-1 plasma viral load using a boosted in vitro infection protocol
    Peter Rusert
    Division of Infectious Diseases, University Hospital Zurich, Switzerland
    Virology 326:113-29. 2004
    ..Measuring viral infectivity may thereby function as an additional, useful marker in monitoring disease progression and evaluating efficacy of antivirals in vivo...
  16. pmc Human immunodeficiency virus type 1 fitness is a determining factor in viral rebound and set point in chronic infection
    Alexandra Trkola
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, 8091 Zurich, Switzerland
    J Virol 77:13146-55. 2003
    ....
  17. doi request reprint Characterization of human immunodeficiency virus type 1 (HIV-1) diversity and tropism in 145 patients with primary HIV-1 infection
    Philip Rieder
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Switzerland
    Clin Infect Dis 53:1271-9. 2011
    ..We analyzed HIV-1 transmission in relation to viral and host characteristics within the Zurich primary HIV-1 infection study...
  18. ncbi request reprint Cellular viral rebound after cessation of potent antiretroviral therapy predicted by levels of multiply spliced HIV-1 RNA encoding nef
    Marek Fischer
    Division of Infectious Diseases and Hospital Epidemiology, Department of Medicine, University Hospital Zurich, CH 8091 Zurich, Switzerland
    J Infect Dis 190:1979-88. 2004
    ....
  19. pmc Profound depletion of HIV-1 transcription in patients initiating antiretroviral therapy during acute infection
    Adrian Schmid
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
    PLoS ONE 5:e13310. 2010
    ..In the current study, HIV-1 RNA transcription patterns in peripheral blood mononuclear cells (PBMC) were monitored during acute cART to assess the effect of early treatment on cellular viral reservoirs...
  20. ncbi request reprint Attenuated and nonproductive viral transcription in the lymphatic tissue of HIV-1-infected patients receiving potent antiretroviral therapy
    Marek Fischer
    Division of Infectious Diseases and Hospital Epidemiology, Department of Medicine, University Hospital Zurich, Zurich, Switzerland
    J Infect Dis 189:273-85. 2004
    ..Thus, residual lymphoid HIV-1 RNA in patients receiving HAART indicates attenuated viral transcription in HIV-1-infected cells that lack virion production...
  21. ncbi request reprint Shifts in cell-associated HIV-1 RNA but not in episomal HIV-1 DNA correlate with new cycles of HIV-1 infection in vivo
    Marek Fischer
    Division of Infectious Diseases and Hospital Epidemiology, Department of Medicine, University Hospital Zurich, 8091 Zurich, Switzerland
    Antivir Ther 8:97-104. 2003
    ..In contrast, expression of HIV-UsRNAPBMC increased during STI and consequently provides a more sensitive, albeit not absolute cellular marker of ongoing HIV-1 replication...
  22. pmc Predictors for the emergence of the 2 multi-nucleoside/nucleotide resistance mutations 69 insertion and Q151M and their impact on clinical outcome in the Swiss HIV cohort study
    Alexandra U Scherrer
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland
    J Infect Dis 203:791-7. 2011
    ..Following detection, individuals with Q151M tended to have lower suppression rates and higher mortality rates, relative to control subjects. Additional studies are needed to verify these findings in non-subtype B infections...
  23. pmc Ambiguous nucleotide calls from population-based sequencing of HIV-1 are a marker for viral diversity and the age of infection
    Roger D Kouyos
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
    Clin Infect Dis 52:532-9. 2011
    ..We assessed whether the fraction of ambiguous nucleotides obtained from bulk sequencing as done for genotypic resistance testing can serve as a proxy of this parameter...
  24. doi request reprint Rational design of HIV-1 fluorescent hydrolysis probes considering phylogenetic variation and probe performance
    Claudia F Althaus
    Division of Infectious Diseases, University Hospital Zurich, University of Zurich, Zurich, Switzerland
    J Virol Methods 165:151-60. 2010
    ..Thus, empirically validated novel principles of FH-probe design regarding conservation and qPCR-performance were identified, which complement and extend current rules for FH-probe design...
  25. doi request reprint HIV-1 transmission after cessation of early antiretroviral therapy among men having sex with men
    Philip Rieder
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland
    AIDS 24:1177-83. 2010
    ..To study transmission dynamics during acute infection, during the aviremic phase over the period of early antiretroviral therapy (ART) and during the phase of viral rebound after early treatment was stopped...
  26. doi request reprint Effect of early antiretroviral therapy during primary HIV-1 infection on cell-associated HIV-1 DNA and plasma HIV-1 RNA
    Sara Gianella
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
    Antivir Ther 16:535-45. 2011
    ..Early initiation of combination antiretroviral therapy (ART) during primary HIV-1 infection may prevent the establishment of large viral reservoirs, possibly resulting in improved control of plasma viraemia rebound after ART cessation...
  27. ncbi request reprint Residual cell-associated unspliced HIV-1 RNA in peripheral blood of patients on potent antiretroviral therapy represents intracellular transcripts
    Marek Fischer
    Department of Medicine, University Hospital Zurich, Switzerland
    Antivir Ther 7:91-103. 2002
    ..As shown by limiting dilution analysis, HIV-1 infected cells with such a repressed viral transcription pattern were observed at high frequencies in PBMC from untreated patients...
  28. pmc Tailored enrichment strategy detects low abundant small noncoding RNAs in HIV-1 infected cells
    Claudia F Althaus
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Ramistrasse 100, CH 8091 Zurich, Switzerland
    Retrovirology 9:27. 2012
    ..Thus, we applied a novel, sequence targeted enrichment strategy to capture HIV-1 derived sncRNAs in HIV-1 infected primary CD4+ T-lymphocytes and macrophages that allows a greater than 100-fold enrichment of low abundant sncRNAs...
  29. pmc Next-generation sequencing of HIV-1 RNA genomes: determination of error rates and minimizing artificial recombination
    Francesca Di Giallonardo
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
    PLoS ONE 8:e74249. 2013
    ..We developed an RT-PCR procedure to generate NGS data useful for reliable haplotype reconstruction and quantification. ..
  30. pmc Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infection
    Saurabh Mehandru
    Aaron Diamond AIDS Research Center, 455 First Avenue, 7th Floor, New York, NY 10016, USA
    J Virol 81:11016-31. 2007
    ..Though safe, the use of MAbs generally delayed, but did not prevent, virologic rebound. Consideration should be given to further pilot studies with alternative combinations of MAbs and perhaps additional novel treatment modalities...
  31. ncbi request reprint HIV replication elicits little cytopathic effects in vivo: analysis of surrogate markers for virus production, cytotoxic T cell response and infected cell death
    Georg A Funk
    Ecology and Evolution, Clausiusstrasse, ETH Zurich Zentrum, Zurich
    J Med Virol 78:1141-6. 2006
    ..25) cytopathic effect (P < 0.05, N = 36). It is concluded that HIV replication elicits little cytopathic effect in productively infected cells and that CD4(+) T lymphocytes are eroded by other mechanisms...
  32. ncbi request reprint HIV-1 p24 may persist during long-term highly active antiretroviral therapy, increases little during short treatment breaks, and its rebound after treatment stop correlates with CD4(+) T cell loss
    Jorg Schupbach
    Swiss National Center for Retroviruses, University of Zurich, Zurich, Switzerland
    J Acquir Immune Defic Syndr 40:250-6. 2005
    ..Persisting p24 despite successful HAART may reflect virus replication in reservoirs not represented by plasma viral load and has implications for the concept of therapeutic vaccination...
  33. ncbi request reprint Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions
    Karin J Metzner
    Aaron Diamond AIDS Research Center, Columbia University, New York, New York, USA
    J Infect Dis 188:1433-43. 2003
    ..Overall, these results indicate that, in subjects undergoing multiple STIs, HIV-1 variants carrying drug-resistance mutations can emerge during periods of increased HIV-1 replication...
  34. ncbi request reprint HIV RNA in plasma rebounds within days during structured treatment interruptions
    Marek Fischer
    Division of Infectious Diseases, University Hospital of Zurich, Switzerland
    AIDS 17:195-9. 2003
    ..To evaluate time to viral rebound in patients undergoing repeated structured treatment interruptions (STI)...